Development of HPV nanovaccine candidate based on IL-15-E7 fusion protein encapsulated in silk-fibroin nanoparticles

2026/07/25 by Maryam Zeynali, Shiva Irani, Mehdi Farokhi +2
Biochemistry, Genetics and Molecular Biology · Environmental Science · Materials Science · #Bacteriophages and microbial interactions #RNA Interference and Gene Delivery #Silk-based biomaterials and applications

paper · doi:10.1016/j.ijpharm.2026.127223

openalex publication_date 2026/07/25 · openalex created_date 2026/07/26 · openalex updated_date 2026/07/31

Citations

• Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies
• Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells
• In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells
• Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity
• Uso de herramientas Web 2.0 en los medios digitales de Ecuador
• Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts
• Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
• Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques
• Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs
• IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4 + T cells for heterosubtypic protection
• A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
• Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7
• Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
• Eradication of Established Tumors by Vaccination With RecombinantBordetella pertussisAdenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein
• Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells
• IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
• Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease
• Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate
• Nanoparticle processing: Understanding and controlling aggregation
• High-risk human papillomavirus-18 uses an mRNA sequence to synthesize oncoprotein E6 in tumors
• Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein